Clorox (NYSE:CLX) Price Target Cut to $125.00 by Analysts at Wells Fargo & Company

Key Points

• Wells Fargo & Company has cut Clorox's price target from $130.00 to $125.00, maintaining an "equal weight" rating on the stock, which indicates a potential upside of 1.21% from its current price.
• Other analysts have also adjusted their ratings, with Citigroup setting a target price of $135.00 (previously $140.00), and Jefferies lowering their target from $167.00 to $145.00 with a "buy" rating.
• Clorox recently reported earnings of $2.87 per share, exceeding analysts' expectations, and the company projects a fiscal year 2026 guidance in the range of $5.95 to $6.30 EPS.

Clorox (NYSE:CLX - Get Free Report) had its target price decreased by investment analysts at Wells Fargo & Company from $130.00 to $125.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an "equal weight" rating on the stock. Wells Fargo & Company's price objective would suggest a potential upside of 1.21% from the company's current price.

A number of other brokerages have also weighed in on CLX. Citigroup reiterated a "neutral" rating and set a $135.00 target price (down previously from $140.00) on shares of Clorox in a research note on Tuesday, July 15th. Jefferies Financial Group lowered their price objective on shares of Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Barclays cut their price objective on Clorox from $129.00 to $119.00 and set an "underweight" rating on the stock in a report on Tuesday, July 15th. JPMorgan Chase & Co. boosted their price target on Clorox from $133.00 to $135.00 and gave the stock a "neutral" rating in a report on Monday, September 8th. Finally, Morgan Stanley cut their price target on shares of Clorox from $150.00 to $137.00 and set an "equal weight" rating on the stock in a report on Friday, August 1st. One investment analyst has rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Reduce" and an average target price of $141.73.

Clorox Stock Performance

CLX stock opened at $123.50 on Thursday. Clorox has a 1-year low of $116.53 and a 1-year high of $171.37. The business's 50-day moving average price is $123.74 and its two-hundred day moving average price is $130.81. The firm has a market cap of $15.11 billion, a PE ratio of 18.87, a P/E/G ratio of 0.97 and a beta of 0.52. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15.

Clorox (NYSE:CLX - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, topping analysts' consensus estimates of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The firm had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.94 billion. During the same period in the prior year, the business earned $1.82 EPS. The company's revenue for the quarter was up 4.5% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, research analysts forecast that Clorox will post 7.15 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Eric H. Reynolds sold 15,041 shares of Clorox stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the sale, the chief operating officer directly owned 54,221 shares in the company, valued at $6,711,475.38. The trade was a 21.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.57% of the company's stock.

Institutional Investors Weigh In On Clorox

Several institutional investors have recently made changes to their positions in the stock. Sonora Investment Management Group LLC increased its stake in shares of Clorox by 2.5% in the first quarter. Sonora Investment Management Group LLC now owns 2,940 shares of the company's stock valued at $433,000 after buying an additional 72 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Clorox by 0.6% during the 1st quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,266 shares of the company's stock worth $1,953,000 after buying an additional 73 shares in the last quarter. Horizon Investments LLC boosted its position in Clorox by 4.4% in the 1st quarter. Horizon Investments LLC now owns 1,768 shares of the company's stock valued at $258,000 after buying an additional 75 shares during the last quarter. Sfmg LLC raised its position in shares of Clorox by 2.8% during the first quarter. Sfmg LLC now owns 2,780 shares of the company's stock worth $409,000 after acquiring an additional 76 shares during the last quarter. Finally, Hancock Whitney Corp boosted its holdings in Clorox by 4.3% in the first quarter. Hancock Whitney Corp now owns 2,064 shares of the company's stock valued at $304,000 after acquiring an additional 86 shares during the last quarter. Hedge funds and other institutional investors own 78.53% of the company's stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.